

=> fil reg

FILE 'REGISTRY' ENTERED AT 07:51:14 ON 05 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 APR 2006 HIGHEST RN 879121-98-9
DICTIONARY FILE UPDATES: 3 APR 2006 HIGHEST RN 879121-98-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d his ful

```
FILE 'REGISTRY' ENTERED AT 07:49:39 ON 05 APR 2006
L1      122 SEA ABB=ON  PLU=ON  AFSRISSGTG|GFSRVSSGGS/SQSP
L2      3 SEA ABB=ON  PLU=ON  L1 AND SQL<51
L3      3 SEA ABB=ON  PLU=ON  L1 AND SQL<101
```

```
FILE 'CAPLUS' ENTERED AT 07:50:45 ON 05 APR 2006
L4      58 SEA ABB=ON  PLU=ON  L1
L5      18 SEA ABB=ON  PLU=ON  L3
```

=> fil reg

FILE 'REGISTRY' ENTERED AT 07:51:29 ON 05 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 APR 2006 HIGHEST RN 879121-98-9
DICTIONARY FILE UPDATES: 3 APR 2006 HIGHEST RN 879121-98-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS
for details.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> d his l1-l3

```
L1      122 S AFSRISSGTG|GFSRVSSGGS/SQSP
L2      3 S L1 AND SQL<51
L3      3 S L1 AND SQL<101
```

=> d sqide3 l3

```
L3      ANSWER 1 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
RN      818376-91-9 REGISTRY
CN      L-Serine, glycyl-L-phenylalanyl-L-seryl-L-arginyl-L-valyl-L-seryl-L-
        serylglycylglycyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN      51: PN: US20040265859 SEQID: 51 claimed sequence
FS      PROTEIN SEQUENCE; STEREOSEARCH
SQL     10
```

PATENT ANNOTATIONS (PNTE):

Sequence Source	Patent Reference
Not Given	US2004265859 claimed SEQID 51

SEQ3 1 Gly-Phe-Ser-Arg-Val-Ser-Ser-Gly-Gly-Ser

HITS AT: 1-10

MF C38 H61 N13 O15

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL


DT.CA CAlplus document type: Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

Absolute stereochemistry.

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d sqide3 l3 2-3

L3 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
RN 818376-90-8 REGISTRY
CN Glycine, L-alanyl-L-phenylalanyl-L-seryl-L-arginyl-L-isoleucyl-L-seryl-L-serylglycyl-L-threonyl- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 50: PN: US20040265859 SEQID: 50 claimed sequence
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 10

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	US2004265859
	claimed
	SEQID 50


SEQ3 1 Ala-Phe-Ser-Arg-Ile-Ser-Ser-Gly-Thr-Gly

HITS AT: 1-10



MF C41 H67 N13 O15
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL
DT.CA Caplus document type: Patent
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PRP (Properties); USES (Uses)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2006 ACS on STN
RN 301546-83-8 REGISTRY
CN L-Valine, L-α-glutamyl-L-arginyl-L-lysyl-L-tryptophylglycyl-L-phenylalanyl-L-seryl-L-arginyl-L-valyl-L-seryl-L-serylglycylglycyl-L-seryl-L-phenylalanyl-L-seryl-L-valyl-L-leucylglycyl- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN 113: PN: US6518256 SEQID: 241 claimed sequence
 CN 16: PN: US20030064947 SEQID: 241 claimed sequence
 CN 16: PN: US6426072 SEQID: 241 claimed sequence
 CN 241: PN: US20020115139 SEQID: 241 claimed protein
 CN 241: PN: US20030138438 SEQID: 241 unclaimed protein
 CN 241: PN: US20040235072 SEQID: 241 unclaimed protein
 CN 241: PN: US20050142620 SEQID: 241 claimed sequence
 CN 241: PN: US20050261166 SEQID: 241 claimed protein
 CN 241: PN: US6706262 SEQID: 241 unclaimed sequence
 CN 241: PN: WO0061612 SEQID: 241 claimed sequence
 CN 241: PN: WO0200174 SEQID: 241 unclaimed sequence
 CN 241: PN: WO2003086175 SEQID: 241 claimed sequence
 CN 242: PN: US6482597 SEQID: 241 unclaimed sequence
 CN 251: PN: US6737514 SEQID: 241 claimed sequence
 CN 252: PN: US20020147143 SEQID: 241 unclaimed sequence
 CN 295: PN: US20020052329 SEQID: 241 claimed sequence
 CN 352: PN: US6531315 SEQID: 241 unclaimed sequence
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 20

PATENT ANNOTATIONS (PNTE):

Sequence	Patent
Source	Reference
Not Given	WO2000061612
	claimed
	SEQID 241
	WO2002000174
	unclaimed
	SEQID 241

SEQ3 1 Glu-Arg-Lys-Trp-Gly-Phe-Ser-Arg-Val-Ser-
 11 Ser-Gly-Gly-Ser-Phe-Ser-Val-Leu-Gly-Val

HITS AT: 5-14

MF C96 H148 N28 O28

SR CA


LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

DT.CA Caplus document type: Patent


RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);
 PREP (Preparation); PRP (Properties); USES (Uses)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

17 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> fil caplus
FILE 'CAPLUS' ENTERED AT 07:52:17 ON 05 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Apr 2006 VOL 144 ISS 15
FILE LAST UPDATED: 4 Apr 2006 (20060404/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>
'OBI' IS DEFAULT SEARCH FIELD FOR 'CAPLUS' FILE

=> d que 14

L1 122 SEA FILE=REGISTRY ABB=ON PLU=ON AFSRISSGTG|GFSRVSSGGS/SQSP
L4 58 SEA FILE=CAPLUS ABB=ON PLU=ON L1

=> d que 15

L1 122 SEA FILE=REGISTRY ABB=ON PLU=ON AFSRISSGTG|GFSRVSSGGS/SQSP
L3 3 SEA FILE=REGISTRY ABB=ON PLU=ON L1 AND SQL<101
L5 18 SEA FILE=CAPLUS ABB=ON PLU=ON L3

=> d .ca 15 1-18

L5 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1242399 CAPLUS
DOCUMENT NUMBER: 143:476392
TITLE: Immunogenic polypeptides, polynucleotides, antibodies
and antigen-presenting cells expressing them for
diagnosis and therapy of lung cancer
INVENTOR(S): Wang, Tongtong; Peckham, David W.; Retter, Marc W.;
Fanger, Gary R.
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 84 pp., Cont.-in-part of U.S.
Ser. No. 313,986.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 22
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005261166	A1	20051124	US 2003-623155	20030717
US 6312695	B1	20011106	US 1998-123912	19980727
US 6660838	B1	20031209	US 1998-221107	19981222
US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
US 6737514	B1	20040518	US 2000-630940	20000802
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002115139	A1	20020822	US 2001-850716	20010507
US 2002147143	A1	20021010	US 2001-897778	20010628
US 2003064947	A1	20030403	US 2001-7700	20011130
US 6960570	B2	20051101		
US 2003138438	A1	20030724	US 2002-117982	20020405
US 2003236209	A1	20031225	US 2002-313986	20021204
US 2004235072	A1	20041125	US 2004-775972	20040210
WO 2005013899	A2	20050217	WO 2004-US23085	20040715
WO 2005013899	C2	20050616		
WO 2005013899	A3	20050818		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

US 2005142620	A1	20050630	US 2004-922124	20040819
PRIORITY APPLN. INFO.:			US 1998-40802	B2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 2000-480884	A2 20000110
			US 2000-510376	B2 20000222
			US 2000-542615	A2 20000404
			US 2000-606421	A2 20000628
			US 2000-630940	A2 20000802
			US 2000-643597	A2 20000821
			US 2000-662786	B2 20000915
			US 2000-685696	B2 20001009
			US 2000-735705	A2 20001212
			US 2001-850716	A2 20010507
			US 2001-897778	A2 20010628
			US 2001-7700	A2 20011130
			US 2002-117982	A2 20020405
			US 2002-313986	A2 20021204
			WO 1999-US5798	A1 19990317
			US 2003-623155	A2 20030717
			US 2004-775972	A 20040210

ED Entered STN: 25 Nov 2005

AB Compns. and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compns. comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

IC ICM A61K038-16

ICS C12Q001-68; C07H021-04; C12N009-00; C07K016-30

INCL 514002000; 435006000; 435183000; 435069100; 435320100; 435325000; 530388800; 536023200

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3, 9, 63

IT	301546-68-9	301546-69-0	301546-70-3	301546-71-4	301546-72-5
	301546-73-6	301546-74-7	301546-75-8	301546-76-9	301546-77-0
	301546-78-1	301546-79-2	301546-80-5	301546-81-6	301546-82-7
	301546-83-8	301546-84-9	301546-85-0	301546-86-1	
	301546-87-2	301546-88-3	301546-89-4	301546-90-7	301546-91-8
	301546-92-9	301546-93-0	387817-58-5	387817-59-6	387817-60-9
	387817-61-0	387817-74-5	387817-77-8	387817-91-6	387817-96-1
	387817-97-2	387817-98-3	387817-99-4	387818-00-0	387818-01-1
	387818-02-2	387818-03-3	387818-04-4	387818-05-5	387818-06-6
	568545-06-2	610312-18-0	610312-19-1	610312-24-8	869759-77-3
	869759-92-2	869759-93-3	869759-94-4	869759-95-5	869759-96-6
	869759-97-7				

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(immunogenic polypeptides, polynucleotides, antibodies and antigen-presenting cells expressing them for diagnosis and therapy of lung cancer)

L5 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:570448 CAPLUS

DOCUMENT NUMBER: 143:71752

TITLE: Lung cancer-associated cDNAs and proteins and their use in diagnosis and therapy

INVENTOR(S): Bangur, Chaitanya S.; Zehentner-Wilkinson, Barbara K.

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of Ser. No. US 2004-775972, filed on 10 Feb 2004 which is CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005142620	A1	20050630	US 2004-922124	20040819
US 6312695	B1	20011106	US 1998-123912	19980727
US 6660838	B1	20031209	US 1998-221107	19981222
US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
US 6737514	B1	20040518	US 2000-630940	20000802
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002115139	A1	20020822	US 2001-850716	20010507
US 2002147143	A1	20021010	US 2001-897778	20010628
US 2003064947	A1	20030403	US 2001-7700	20011130
US 6960570	B2	20051101		
US 2003138438	A1	20030724	US 2002-117982	20020405
US 2003236209	A1	20031225	US 2002-313986	20021204
US 2005261166	A1	20051124	US 2003-623155	20030717
US 2004235072	A1	20041125	US 2004-775972	20040210
PRIORITY APPLN. INFO.:			US 1998-40802	B2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 2000-480884	A2 20000110
			US 2000-510376	B2 20000222
			US 2000-542615	A2 20000404
			US 2000-606421	A2 20000628
			US 2000-630940	A2 20000802
			US 2000-643597	A2 20000821
			US 2000-662786	B2 20000915
			US 2000-685696	B2 20001009
			US 2000-735705	A2 20001212
			US 2001-850716	B2 20010507
			US 2001-897778	B2 20010628
			US 2001-7700	A2 20011130

US 2002-117982	B2 20020405
US 2002-313986	A2 20021204
US 2003-623155	A2 20030717
US 2004-775972	A2 20040210
WO 1999-US5798	A1 19990317

ED Entered STN: 01 Jul 2005

AB The cDNAs and corresponding proteins corresponding to mRNAs differentially expressed in lung squamous cell carcinoma and lung adenocarcinoma are disclosed. Antibodies to the lung cancer-associated proteins and probes for lung cancer-associated nucleic acids may be used in diagnosis of lung cancer. The proteins and cDNAs, antibodies to the proteins, T cells specific for these tumor proteins, and antigen-presenting cells expressing an epitope of these proteins may be used in treatment of lung cancer, e.g., in vaccines. Thus, many novel lung cancer-associated cDNAs/proteins were identified and their expression in normal and tumor tissues examined. Some of these cDNAs were expressed in Escherichia coli, HEK293, and CHL-1 cells. N- and C-terminal fragments of one of the proteins were expressed as fusions with Mycobacterium tuberculosis 32-kilodalton serine proteinase-derived peptide. CTL lines specific for one of the tumor antigens were generated by in vitro whole-gene priming. In particular, the present invention provides use of the L523S protein for diagnosis of cervical cancer.

IC ICM G01N033-574

ICS C07K016-30

INCL 435007230; 530388800

CC 1-6 (Pharmacology)

Section cross-reference(s): 3, 6, 14, 15

IT 301546-68-9P 301546-69-0P 301546-70-3P 301546-71-4P 301546-72-5P
 301546-73-6P 301546-74-7P 301546-75-8P 301546-76-9P 301546-77-0P
 301546-78-1P 301546-79-2P 301546-80-5P 301546-81-6P 301546-82-7P
301546-83-8P 301546-84-9P 301546-85-0P 301546-86-1P
 301546-87-2P 301546-88-3P 301546-89-4P 301546-90-7P 301546-91-8P
 301546-92-9P 301546-93-0P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
 DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL
 (Biological study); PREP (Preparation); USES (Uses)
 (peptide derived from lung tumor antigen L528S; lung tumor
 polypeptides, polynucleotides, and antibodies for cancer diagnosis and
 treatment)

L5 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1996 CAPLUS

DOCUMENT NUMBER: 142:87715

TITLE: Protein and cDNA sequences of a novel human
 calcium-activated chloride channel protein CLCA2 and
 their use in anti-metastatic therapy

INVENTOR(S): Pauli, Bendicht U.; Elble, Randolph C.; Gruber, Achim
 D.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 85 pp., Cont.-in-part of U.S.
 Ser. No. 55,412.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2004265859	A1	20041230	US 2004-779949	20040217

US 6309857	B1	20011030	US 1998-193562	19981117
US 2003059861	A1	20030327	US 2001-55412	20011029
US 6692939	B2	20040217		
PRIORITY APPLN. INFO.:			US 1997-65922P	P 19971117
			US 1998-193562	A3 19981117
			US 2001-55412	A2 20011029
			US 1998-193561	A3 19981117

AB Nucleotide sequences which encode a mammalian lung endothelial cell adhesion mol. are disclosed. Also disclosed are nucleotide sequences which encode a lung endothelial cell adhesion mol.-associated protein. Recombinant lung endothelial cell adhesion mol. or recombinant lung endothelial cell adhesion mol.-associated protein may be obtained by culturing in a medium a host cell genetically engineered to contain and express a nucleotide sequence according to the present invention, and recovering the recombinant lung endothelial cell adhesion mol.-associated protein or recombinant lung endothelial cell adhesion mol.-associated protein from the culture medium.

ICS G01N033-574; C07H021-04; A61K038-08

CC 3-3 (Biochemical Genetics)

IT 818376-90-8P 818376-91-9P

L5 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1019645 CAPLUS

DOCUMENT NUMBER: 142:3040

TITLE: Compositions comprising cancer antigen sequences for the therapy and diagnosis of lung cancer

INVENTOR(S): Henderson, Robert A.; Wang, Tongtong; Bangur, Chaitanya S.

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 86 pp., Cont.-in-part of U.S. Ser. No. 623,155.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004235072	A1	20041125	US 2004-775972	20040210
US 6312695	B1	20011106	US 1998-123912	19980727
US 6660838	B1	20031209	US 1998-221107	19981222
US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628

US 6737514	B1	20040518	US 2000-630940	20000802
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002115139	A1	20020822	US 2001-850716	20010507
US 2002147143	A1	20021010	US 2001-897778	20010628
US 2003064947	A1	20030403	US 2001-7700	20011130
US 6960570	B2	20051101		
US 2003138438	A1	20030724	US 2002-117982	20020405
US 2003236209	A1	20031225	US 2002-313986	20021204
US 2005261166	A1	20051124	US 2003-623155	20030717
WO 2005013899	A2	20050217	WO 2004-US23085	20040715
WO 2005013899	C2	20050616		
WO 2005013899	A3	20050818		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005142620	A1	20050630	US 2004-922124	20040819
PRIORITY APPLN. INFO.:			US 1998-40802	B2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 2000-480884	A2 20000110
			US 2000-510376	A2 20000222
			US 2000-542615	A2 20000404
			US 2000-606421	A2 20000628
			US 2000-630940	A2 20000802
			US 2000-643597	A2 20000821
			US 2000-662786	B2 20000915
			US 2000-685696	B2 20001009
			US 2000-735705	A2 20001212
			US 2001-850716	B2 20010507
			US 2001-897778	A2 20010628
			US 2001-7700	A2 20011130
			US 2002-117982	A2 20020405
			US 2002-313986	A2 20021204
			US 2003-623155	A2 20030717
			WO 1999-US5798	A1 19990317
			US 2004-775972	A 20040210

ED Entered STN: 26 Nov 2004

AB The present invention provides compns. comprising cancer antigen sequences and methods for the therapy and diagnosis of cancer, particularly lung cancer. Specifically, the method comprises the steps of: (a) contacting a biol. sample obtained from the patient with a binding agent that binds to a lung cancer antigen L762P; (b) detecting in the sample an amount of polypeptide that binds to the binding agent; and (c) comparing the amount of polypeptide to a predetd. cut-off value and therefrom determining the presence of a lung cancer in the patient. Illustrative compns. comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells

expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment lung cancer.

IC ICM G01N033-574

INCL 435007230

CC 9-2 (Biochemical Methods)

Section cross-reference(s): 1, 3, 15

IT	301546-68-9	301546-69-0	301546-70-3	301546-71-4	301546-72-5
	301546-73-6	301546-74-7	301546-75-8	301546-76-9	301546-77-0
	301546-78-1	301546-79-2	301546-80-5	301546-81-6	301546-82-7
	301546-83-8	301546-84-9	301546-85-0	301546-86-1	
	301546-87-2	301546-88-3	301546-89-4	301546-90-7	301546-91-8
	301546-92-9	301546-93-0	352468-93-0	387817-58-5	387817-59-6
	387817-60-9	387817-61-0	387817-62-1	387817-63-2	387817-64-3
	387817-65-4	387817-66-5	387817-67-6	387817-68-7	387817-69-8
	387817-70-1	387817-71-2	387817-72-3	387817-73-4	387817-74-5
	387817-75-6	387817-76-7	387817-77-8	387817-78-9	387817-79-0
	387817-80-3	387817-81-4	387817-82-5	387817-83-6	387817-84-7
	387817-85-8	387817-86-9	387817-87-0	387817-88-1	387817-89-2
	387817-90-5	387817-91-6	387817-92-7	387817-93-8	387817-94-9
	387817-95-0	387817-96-1	387817-97-2	387817-98-3	387817-99-4
	387818-00-0	387818-01-1	387818-02-2	387818-03-3	387818-04-4
	387818-05-5	387818-06-6	506413-96-3	506413-97-4	568545-06-2
	610312-18-0	610312-19-1	610312-20-4	610312-21-5	610312-22-6
	610312-23-7	610312-24-8	610312-25-9	610312-26-0	610312-27-1
	610312-28-2	610312-29-3	610312-30-6	610312-31-7	610312-32-8
	610312-33-9	610312-34-0	610312-35-1	610312-36-2	610312-37-3
	610312-38-4	610312-39-5	610312-40-8	610312-41-9	610312-42-0
	610312-43-1	610312-44-2	610312-45-3	610312-46-4	610312-47-5
	610312-48-6	610312-49-7	610312-50-0	610312-51-1	610312-52-2
	610312-53-3	610312-54-4	610312-55-5	610312-56-6	798322-39-1
	798322-41-5	798322-43-7	798322-77-7	798322-80-2	798322-81-3
	798322-84-6	798322-86-8	798322-90-4	798322-93-7	798322-94-8
	798322-96-0	798322-98-2	798323-00-9	798323-49-6	798323-50-9
	798324-36-4	798324-37-5	798324-38-6	798324-39-7	798324-40-0
	798324-41-1	798324-42-2	798324-44-4	798324-46-6	798324-48-8
	798324-50-2	798324-52-4	798324-55-7	798324-59-1	798324-64-8
	798324-78-4	798324-82-0	798324-85-3	798324-88-6	798324-97-7
	798325-03-8	798325-04-9	798325-05-0	798325-06-1	798325-07-2
	798325-08-3	798325-09-4	798325-11-8	798325-13-0	798325-15-2
	798325-19-6	798325-20-9	798325-21-0		

RL: PRP (Properties)

(unclaimed protein sequence; compns. comprising cancer antigen sequences for the therapy and diagnosis of lung cancer)

L5 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:403055 CAPLUS

DOCUMENT NUMBER: 140:405473

TITLE: Lung tumor proteins, polynucleotides and antibodies for lung cancer therapy and diagnosis

INVENTOR(S): Wang, Tongtong; Fan, Liqun; Kalos, Michael D.; Bangur, Chaitanya S.; Hosken, Nancy A.; Fanger, Gary R.; Li, Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.; Henderson, Robert A.; McNeill, Patricia D.

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: U.S., 230 pp., Cont.-in-part of U.S. 6,531,315.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6737514	B1	20040518	US 2000-630940	20000802
US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
WO 2002000174	A2	20020103	WO 2001-US21065	20010628
WO 2002000174	A3	20030410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001073149	A5	20020108	AU 2001-73149	20010628
US 2002147143	A1	20021010	US 2001-897778	20010628
EP 1319069	A2	20030618	EP 2001-952390	20010628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004513615	T2	20040513	JP 2002-504957	20010628
US 2003064947	A1	20030403	US 2001-7700	20011130
US 6960570	B2	20051101		
US 2003138438	A1	20030724	US 2002-117982	20020405
US 2003236209	A1	20031225	US 2002-313986	20021204
US 2005261166	A1	20051124	US 2003-623155	20030717
US 2004235072	A1	20041125	US 2004-775972	20040210
US 2005142620	A1	20050630	US 2004-922124	20040819
PRIORITY APPLN. INFO.:			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 2000-480884	A2 20000110
			US 2000-510376	A2 20000222
			US 2000-542615	A2 20000404
			US 2000-606421	A2 20000628
			US 1998-40802	B2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			WO 1999-US5798	A1 19990317
			US 2000-630940	A2 20000802
			US 2000-643597	A2 20000821
			US 2000-662786	A2 20000915
			US 2000-685696	A2 20001009
			US 2000-735705	A 20001212
			US 2001-850716	A 20010507
			US 2001-897778	A2 20010628
			WO 2001-US21065	W 20010628
			US 2001-7700	A2 20011130
			US 2002-117982	A2 20020405
			US 2002-313986	A2 20021204

US 2003-623155

A2 20030717

US 2004-775972

A2 20040210

ED Entered STN: 19 May 2004

AB Compns. and methods for the therapy and diagnosis of cancer, such as lung cancer, are disclosed. Compns. may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. The lung tumor proteins are identified and characterized from cDNA libraries of human lung squamous cell carcinoma and human lung adenocarcinoma. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a lung tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as lung cancer. Diagnostic methods based on detecting a lung tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IC ICM C07K016-00

ICS C07K014-00; C07K017-00; A61K038-00; A61K039-395; A61K039-40;
C07H021-02; C07H021-04

INCL 530387700; 424130100; 424178100; 530300000; 530350000; 536023100

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3, 9, 63

IT 301546-68-9P 301546-69-0P 301546-70-3P 301546-71-4P 301546-72-5P
301546-73-6P 301546-74-7P 301546-75-8P 301546-76-9P 301546-77-0P
301546-78-1P 301546-79-2P 301546-80-5P 301546-81-6P 301546-82-7P
301546-83-8P 301546-84-9P 301546-85-0P 301546-86-1P
301546-87-2P 301546-88-3P 301546-89-4P 301546-90-7P 301546-91-8P
301546-92-9P 301546-93-0P 387817-58-5P 387817-59-6P 690276-84-7P
690276-85-8P 690276-86-9P 690276-87-0P 690276-88-1P 690276-89-2P

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified);
DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)

(lung tumor proteins, polynucleotides and antibodies for lung cancer
therapy and diagnosis)

REFERENCE COUNT: 70 THERE ARE 70 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:212103 CAPLUS

DOCUMENT NUMBER: 140:251748

TITLE: Genes showing altered levels of expression in lung
cancer and their use in diagnosis and as a target for
therapy

INVENTOR(S): Wang, Tongtong; Hosken, Nancy A.; Kalos, Michael D.;
Fanger, Gary R.

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: U.S., 154 pp., Cont.-in-part of U.S. Ser. No. 466,396.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6706262	B1	20040316	US 1999-476496	19991230
US 6312695	B1	20011106	US 1998-123912	19980727
US 6660838	B1	20031209	US 1998-221107	19981222
WO 9947674	A2	19990923	WO 1999-US5798	19990317
WO 9947674	A3	20000120		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,

Brandon Fetterolf 10/779,949

KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 6821518 B1 20041123 US 1999-285479 19990402
 US 2003119763 A1 20030626 US 1999-466396 19991217
 US 6696247 B2 20040224
 US 6482597 B1 20021119 US 2000-480884 20000110
 CA 2369578 AA 20001019 CA 2000-2369578 20000403
 WO 2000061612 A2 20001019 WO 2000-US8896 20000403
 WO 2000061612 A3 20010426
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR,
 CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
 ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
 LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
 SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 EP 1169347 A2 20020109 EP 2000-920102 20000403
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 BR 2000009505 A 20020611 BR 2000-9505 20000403
 JP 2002543769 T2 20021224 JP 2000-611554 20000403
 NZ 514818 A 20040430 NZ 2000-514818 20000403
 US 6518256 B1 20030211 US 2000-542615 20000404
 US 6531315 B1 20030311 US 2000-606421 20000628
 US 6737514 B1 20040518 US 2000-630940 20000802
 US 2002052329 A1 20020502 US 2000-735705 20001212
 US 2002147143 A1 20021010 US 2001-897778 20010628
 US 2003064947 A1 20030403 US 2001-7700 20011130
 US 6960570 B2 20051101
 US 2003138438 A1 20030724 US 2002-117982 20020405
 US 2003236209 A1 20031225 US 2002-313986 20021204
 US 2005261166 A1 20051124 US 2003-623155 20030717
 US 2004235072 A1 20041125 US 2004-775972 20040210
 US 2005142620 A1 20050630 US 2004-922124 20040819
 PRIORITY APPLN. INFO.: US 1998-40802 B2 19980318
 US 1998-123912 A2 19980727
 US 1998-221107 A2 19981222
 WO 1999-US5798 A2 19990317
 US 1999-285479 A2 19990402
 US 1999-466396 A2 19991217
 US 1998-40984 A 19980318
 US 1998-123933 A 19980727
 US 1999-476496 A2 19991230
 US 2000-480884 A 20000110
 US 2000-510376 A 20000222
 WO 2000-US8896 W 20000403
 US 2000-542615 A2 20000404
 US 2000-606421 A2 20000628
 US 2000-630940 A2 20000802
 US 2000-643597 A2 20000821
 US 2000-662786 A2 20000915
 US 2000-685696 A2 20001009
 US 2000-735705 A2 20001212
 US 2001-850716 A2 20010507
 US 2001-897778 A2 20010628

US 2001-7700	A2 20011130
US 2002-117982	A2 20020405
US 2002-313986	A2 20021204
US 2003-623155	A2 20030717
US 2004-775972	A2 20040210

ED Entered STN: 17 Mar 2004

AB Genes that show altered levels of expression in neoplastic lung tissue are identified. The genes and gene products may be useful as targets for the diagnosis and treatment of lung cancer (no data). Vaccines and pharmaceutical compns. for immunotherapy of lung cancer comprising such polypeptides, or DNA mols. encoding such polypeptides, are also provided, together with DNA mols. for preparing the inventive polypeptides.

IC ICM A01N063-00

ICS C07H021-04; C12N015-00; C12N005-00; C12N015-63

INCL 424093200; 536023500; 435320100; 435325000; 435455000

CC 14-1 (Mammalian Pathological Biochemistry)

Section cross-reference(s): 3, 15

IT	301546-68-9	301546-69-0	301546-70-3	301546-71-4	301546-72-5
	301546-73-6	301546-74-7	301546-75-8	301546-76-9	301546-77-0
	301546-78-1	301546-79-2	301546-80-5	301546-81-6	301546-82-7
	301546-83-8	301546-84-9	301546-85-0	301546-86-1	
	301546-87-2	301546-88-3	301546-89-4	301546-90-7	301546-91-8
	301546-92-9	301546-93-0			

RL: PRP (Properties)

(unclaimed sequence; genes showing altered levels of expression in lung cancer and their use in diagnosis and as a target for therapy)

REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:836746 CAPLUS

DOCUMENT NUMBER: 139:333094

TITLE: Lung cancer-associated cDNAs and proteins and their use in diagnosis and therapy

INVENTOR(S): Mericle, Barbara; Fanger, Gary R.; Vedvick, Thomas S.; Carter, Darrick; Watanabe, Yoshihiro; Henderson, Robert A.; Kalos, Michael D.; Spies, Gregory A.; Foy, Teresa M.; Fan, Liqun; Wang, Tongtong; McNabb, Andria; Reed, Steven G.

PATENT ASSIGNEE(S): Corixa Corporation, USA; et al.

SOURCE: PCT Int. Appl., 456 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2003086175	A2	20031023	WO 2003-US10945	20030407
WO 2003086175	A3	20040923		
WO 2003086175	C1	20050210		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003138438	A1	20030724	US 2002-117982	20020405
US 2003236209	A1	20031225	US 2002-313986	20021204
EP 1496743	A2	20050119	EP 2003-723955	20030407

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

JP 2005522209	T2	20050728	JP 2003-583206	20030407
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.:

US 2002-117982	A	20020405
US 2002-313986	A	20021204
US 1998-40802	B2	19980318
US 1998-123912	A2	19980727
US 1998-221107	A2	19981222
US 1999-285479	A2	19990402
US 1999-466396	A2	19991217
US 1999-476496	A2	19991230
US 2000-480884	A2	20000110
US 2000-510376	A2	20000222
US 2000-542615	A2	20000404
US 2000-606421	A2	20000628
US 2000-630940	A2	20000802
US 2000-643597	A2	20000821
US 2000-662786	B2	20000915
US 2000-685696	A2	20001009
US 2000-735705	A2	20001212
US 2001-850716	A2	20010507
US 2001-897778	A2	20010628
US 2001-7700	A2	20011130
WO 2003-US10945	W	20030407

ED Entered STN: 24 Oct 2003

AB The cDNAs and corresponding proteins corresponding to mRNAs differentially expressed in lung squamous cell carcinoma and lung adenocarcinoma are disclosed. Antibodies to the lung cancer-associated proteins and probes for lung cancer-associated nucleic acids may be used in diagnosis of lung cancer. The proteins and cDNAs, antibodies to the proteins, T cells specific for these tumor proteins, and antigen-presenting cells expressing an epitope of these proteins may be used in treatment of lung cancer, e.g., in vaccines. Thus, many novel lung cancer-associated cDNAs/proteins were identified and their expression in normal and tumor tissues examined. Some of these cDNAs were expressed in *Escherichia coli*, HEK293, and CHL-1 cells. N- and C-terminal fragments of one of the proteins were expressed as fusions with *Mycobacterium tuberculosis* 32-kilodalton serine proteinase-derived peptide. CTL lines specific for one of the tumor antigens were generated by in vitro whole-gene priming.

IC ICM A61B

CC 1-6 (Pharmacology)

Section cross-reference(s): 3, 6, 14, 15

IT	301546-68-9P	301546-69-0P	301546-70-3P	301546-71-4P	301546-72-5P
	301546-73-6P	301546-74-7P	301546-75-8P	301546-76-9P	301546-77-0P
	301546-78-1P	301546-79-2P	301546-80-5P	301546-81-6P	301546-82-7P
	301546-83-8P	301546-84-9P	301546-85-0P	301546-86-1P	
	301546-87-2P	301546-88-3P	301546-89-4P	301546-90-7P	301546-91-8P
	301546-92-9P	301546-93-0P			

RL: BPN (Biosynthetic preparation); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(peptide derived from lung tumor antigen L528S; compns. and methods for the therapy and diagnosis of lung cancer)

L5 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:570453 CAPLUS
DOCUMENT NUMBER: 139:132437
TITLE: Lung cancer antigens and cDNAs encoding them and their diagnostic, prophylactic and therapeutic uses
INVENTOR(S): Mericle, Barbara; Fanger, Gary R.; Vedvick, Thomas S.; Carter, Darrick; Watanabe, Yoshihiro; Henderson, Robert A.; Kalos, Michael D.; Spies, A. Gregory; Foy, Teresa M.; Fan, Liqun; Wang, Tongtong
PATENT ASSIGNEE(S): Corixa Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 75 pp., Cont.-in-part of U.S. Ser. No. 7,700.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 22
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003138438	A1	20030724	US 2002-117982	20020405
US 6312695	B1	20011106	US 1998-123912	19980727
US 6660838	B1	20031209	US 1998-221107	19981222
US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
US 6737514	B1	20040518	US 2000-630940	20000802
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002115139	A1	20020822	US 2001-850716	20010507
US 2002147143	A1	20021010	US 2001-897778	20010628
US 2003064947	A1	20030403	US 2001-7700	20011130
US 6960570	B2	20051101		
US 2003236209	A1	20031225	US 2002-313986	20021204
WO 2003086175	A2	20031023	WO 2003-US10945	20030407
WO 2003086175	A3	20040923		
WO 2003086175	C1	20050210		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1496743	A2	20050119	EP 2003-723955	20030407
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005522209	T2	20050728	JP 2003-583206	20030407
US 2005261166	A1	20051124	US 2003-623155	20030717
US 2004235072	A1	20041125	US 2004-775972	20040210
US 2005142620	A1	20050630	US 2004-922124	20040819
PRIORITY APPLN. INFO.:				US 1998-40802 B2 19980318
				US 1998-123912 A2 19980727
				US 1998-221107 A2 19981222

US 1999-285479	A2 19990402
US 1999-466396	A2 19991217
US 1999-476496	A2 19991230
US 2000-480884	A2 20000110
US 2000-510376	A2 20000222
US 2000-542615	A2 20000404
US 2000-606421	A2 20000628
US 2000-630940	A2 20000802
US 2000-643597	A2 20000821
US 2000-662786	B2 20000915
US 2000-685696	A2 20001009
US 2000-735705	A2 20001212
US 2001-850716	A2 20010507
US 2001-897778	A2 20010628
US 2001-7700	A2 20011130
WO 1999-US5798	A1 19990317
US 2002-117982	A2 20020405
US 2002-313986	A 20021204
WO 2003-US10945	W 20030407
US 2003-623155	A2 20030717
US 2004-775972	A2 20040210

ED Entered STN: 25 Jul 2003

AB Lung cancer-specific antigens are identified and characterized and cDNAs encoding a number of them are cloned and characterized. The antigens, or epitopes derived from them may be useful in the diagnosis, prevention, or treatment of lung cancer. Characterization of a number of antigens, including tissue distribution and the identification of T cell epitopes is demonstrated.

IC ICM A61K039-00

INCL 424185100; 424277100

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3, 9, 63

IT 301546-68-9	301546-69-0	301546-70-3	301546-71-4	301546-72-5
301546-73-6	301546-74-7	301546-75-8	301546-76-9	301546-77-0
301546-78-1	301546-79-2	301546-80-5	301546-81-6	301546-82-7
301546-83-8	301546-84-9	301546-85-0	301546-86-1	
301546-87-2	301546-88-3	301546-89-4	301546-90-7	301546-91-8
301546-92-9	301546-93-0	387817-58-5	387817-59-6	387817-60-9
387817-61-0	387817-62-1	387817-63-2	387817-64-3	387817-65-4
387817-66-5	387817-67-6	387817-68-7	387817-69-8	387817-70-1
387817-71-2	387817-72-3	387817-73-4	387817-74-5	387817-75-6
387817-76-7	387817-77-8	387817-78-9	387817-79-0	387817-80-3
387817-81-4	387817-82-5	387817-83-6	387817-84-7	387817-85-8
387817-86-9	387817-87-0	387817-88-1	387817-89-2	387817-90-5
387817-91-6	387817-92-7	387817-93-8	387817-94-9	387817-95-0
387817-96-1	387817-97-2	387817-98-3	387817-99-4	387818-00-0
387818-01-1	387818-02-2	387818-03-3	387818-04-4	387818-05-5
387818-06-6	506413-96-3	506413-97-4		

RL: PRP (Properties)

(unclaimed sequence; lung cancer antigens and cDNAs encoding them and their diagnostic, prophylactic and therapeutic uses)

L5 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:261014 CAPLUS

DOCUMENT NUMBER: 138:302631

TITLE: Lung carcinoma-derived polypeptides, polynucleotides, probes and primers, and antibodies for cancer therapy and diagnosis

INVENTOR(S): Wang, Tongtong; Wang, Aijun; Skeiky, Yasir A. W.; Li, Samuel X.; Kalos, Michael D.; Henderson, Robert A.;

Brandon Fetterolf 10/779,949

McNeill, Patricia D.; Fanger, Neil; Retter, Marc W.;
Durham, Margarita; Fanger, Gary R.; Vedvick, Thomas
S.; Carter, Darrick; Watanabe, Yoshihiro; Peckham,
David W.; Cai, Feng; Foy, Teresa M.

PATENT ASSIGNEE(S):

Corixa Corporation, USA

SOURCE:

U.S. Pat. Appl. Publ., 296 pp., Cont.-in-part of U.S.
Ser. No. 897,778.

CODEN: USXXCO

DOCUMENT TYPE:

Patent

LANGUAGE:

English

FAMILY ACC. NUM. COUNT:

22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 2003064947	A1	20030403	US 2001-7700	20011130
US 6960570	B2	20051101		
US 6312695	B1	20011106	US 1998-123912	19980727
US 6660838	B1	20031209	US 1998-221107	19981222
US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
US 6737514	B1	20040518	US 2000-630940	20000802
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002115139	A1	20020822	US 2001-850716	20010507
US 2002147143	A1	20021010	US 2001-897778	20010628
US 2003138438	A1	20030724	US 2002-117982	20020405
US 2003236209	A1	20031225	US 2002-313986	20021204
US 2005261166	A1	20051124	US 2003-623155	20030717
US 2004235072	A1	20041125	US 2004-775972	20040210
US 2005142620	A1	20050630	US 2004-922124	20040819
PRIORITY APPLN. INFO.:			US 1998-40802	A2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 2000-480884	A2 20000110
			US 2000-510376	A2 20000222
			US 2000-542615	A2 20000404
			US 2000-606421	A2 20000628
			US 2000-630940	A2 20000802
			US 2000-643597	A2 20000821
			US 2000-662786	A2 20000915
			US 2000-685696	A2 20001009
			US 2000-735705	A2 20001212
			US 2001-850716	A2 20010507
			US 2001-897778	A2 20010628
			WO 1999-US5798	A1 19990317
			US 2001-7700	A2 20011130
			US 2002-117982	A2 20020405
			US 2002-313986	A2 20021204
			US 2003-623155	A2 20030717
			US 2004-775972	A2 20040210

ED Entered STN: 04 Apr 2003

AB Compns. and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compns. comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The lung tumor antigens and encoding polynucleotides are isolated and characterized from human lung squamous cell carcinoma cDNA expression library by PCR-based subtraction, and human monoclonal antibodies and hybridomas are generated from transgenic mice.

IC ICM A61K048-00

INCL 514044000; 424093210

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3, 9, 63

IT 301546-68-9 301546-69-0 301546-70-3 301546-71-4 301546-72-5
 301546-73-6 301546-74-7 301546-75-8 301546-76-9 301546-77-0
 301546-78-1 301546-79-2 301546-80-5 301546-81-6 301546-82-7
301546-83-8 301546-84-9 301546-85-0 301546-86-1
 301546-87-2 301546-88-3 301546-89-4 301546-90-7 301546-91-8
 301546-92-9 301546-93-0 387817-58-5 387817-59-6 387817-60-9
 387817-61-0 387817-62-1 387817-63-2 387817-64-3 387817-65-4
 387817-66-5 387817-67-6 387817-68-7 387817-69-8 387817-70-1
 387817-71-2 387817-72-3 387817-73-4 387817-74-5 387817-75-6
 387817-76-7 387817-77-8 387817-78-9 387817-79-0 387817-80-3
 387817-81-4 387817-82-5 387817-83-6 387817-84-7 387817-85-8
 387817-86-9 387817-87-0 387817-88-1 387817-89-2 387817-90-5
 387817-91-6 387817-92-7 387817-93-8 387817-94-9 387817-95-0
 387817-96-1 387817-97-2 387817-98-3 387817-99-4 387818-00-0
 387818-01-1 387818-02-2 387818-03-3 387818-04-4 387818-05-5
 387818-06-6 506413-96-3 506413-97-4 506450-56-2 506450-57-3
 506450-58-4 506450-59-5 506450-60-8 506450-61-9 506450-62-0
 506450-63-1 506450-64-2

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lung carcinoma-derived polypeptides, polynucleotides, probes and primers, and antibodies for cancer therapy and diagnosis)

L5 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:196912 CAPLUS

DOCUMENT NUMBER: 138:236911

TITLE: Lung tumor proteins, polynucleotides and antibodies for therapy and diagnosis of lung cancer

INVENTOR(S): Wang, Tongtong; Fan, Liqun; Kalos, Michael D.; Bangur, Chaitanya S.; Hosken, Nancy A.; Fanger, Gary R.; Li, Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: U.S., 225 pp., Cont.-in-part of U.S. Ser. No. 542,615. CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6531315	B1	20030311	US 2000-606421	20000628
US 6312695	B1	20011106	US 1998-123912	19980727
US 6660838	B1	20031209	US 1998-221107	19981222
WO 9947674	A2	19990923	WO 1999-US5798	19990317
WO 9947674	A3	20000120		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

Brandon Fetterolf 10/779,949

DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 US 6821518 B1 20041123 US 1999-285479 19990402
 US 2003119763 A1 20030626 US 1999-466396 19991217
 US 6696247 B2 20040224
 US 6706262 B1 20040316 US 1999-476496 19991230
 US 6482597 B1 20021119 US 2000-480884 20000110
 US 6518256 B1 20030211 US 2000-542615 20000404
 US 6737514 B1 20040518 US 2000-630940 20000802
 US 2002052329 A1 20020502 US 2000-735705 20001212
 WO 2002000174 A2 20020103 WO 2001-US21065 20010628
 WO 2002000174 A3 20030410
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
 UZ, VN, YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG,
 KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN,
 GW, ML, MR, NE, SN, TD, TG
 AU 2001073149 A5 20020108 AU 2001-73149 20010628
 US 2002147143 A1 20021010 US 2001-897778 20010628
 EP 1319069 A2 20030618 EP 2001-952390 20010628
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004513615 T2 20040513 JP 2002-504957 20010628
 US 2003064947 A1 20030403 US 2001-7700 20011130
 US 6960570 B2 20051101
 US 2003138438 A1 20030724 US 2002-117982 20020405
 US 2003236209 A1 20031225 US 2002-313986 20021204
 US 2005261166 A1 20051124 US 2003-623155 20030717
 US 2004235072 A1 20041125 US 2004-775972 20040210
 US 2005142620 A1 20050630 US 2004-922124 20040819
 PRIORITY APPLN. INFO.:
 US 1998-40802 B2 19980318
 US 1998-123912 A2 19980727
 US 1998-221107 A2 19981222
 WO 1999-US5798 A1 19990317
 US 1999-285479 A2 19990402
 US 1999-466396 A2 19991217
 US 1999-476496 A2 19991230
 US 2000-480884 A2 20000110
 US 2000-510376 A2 20000222
 US 2000-542615 A2 20000404
 US 1998-40984 A 19980318
 US 1998-123933 A 19980727
 US 2000-606421 A2 20000628
 US 2000-630940 A2 20000802
 US 2000-643597 A2 20000821
 US 2000-662786 A2 20000915
 US 2000-685696 A2 20001009
 US 2000-735705 A 20001212
 US 2001-850716 A 20010507
 US 2001-897778 A2 20010628

WO 2001-US21065	W 20010628
US 2001-7700	A2 20011130
US 2002-117982	A2 20020405
US 2002-313986	A2 20021204
US 2003-623155	A2 20030717
US 2004-775972	A2 20040210

ED Entered STN: 12 Mar 2003

AB Compns. and methods for the therapy and diagnosis of cancer, such as lung cancer, are disclosed. Compns. may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a lung tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as lung cancer. Diagnostic methods based on detecting a lung tumor protein, or mRNA encoding such a protein, in a sample are also provided.

IC ICM C12N005-08

ICS C12N005-06; A61K039-00

INCL 435372300; 435326000; 424184100; 424185110

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3, 9, 63

IT 301546-68-9	301546-69-0	301546-70-3	301546-71-4	301546-72-5
301546-73-6	301546-74-7	301546-75-8	301546-76-9	301546-77-0
301546-78-1	301546-79-2	301546-80-5	301546-81-6	301546-82-7
301546-83-8	301546-84-9	301546-85-0	301546-86-1	
301546-87-2	301546-88-3	301546-89-4	301546-90-7	301546-91-8
301546-92-9	301546-93-0			

RL: PRP (Properties)

(unclaimed sequence; lung tumor proteins, polynucleotides and antibodies for therapy and diagnosis of lung cancer)

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:113384 CAPLUS

DOCUMENT NUMBER: 138:168806

TITLE: Lung tumor polypeptides, polynucleotides, and antibodies for therapy and diagnosis of lung cancer

INVENTOR(S): Wang, Tongtong; Fan, Liqun; Kalos, Michael D.; Bangur, Chaitanya S.; Hosken, Nancy A.; Fanger, Gary R.

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: U.S., 203 pp., Cont.-in-part of U.S. Ser. No. 510,376.
CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6518256	B1	20030211	US 2000-542615	20000404
US 6312695	B1	20011106	US 1998-123912	19980727
US 6660838	B1	20031209	US 1998-221107	19981222
WO 9947674	A2	19990923	WO 1999-US5798	19990317
WO 9947674	A3	20000120		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
 ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
 CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
US 6531315	B1	20030311	US 2000-606421	20000628
US 6737514	B1	20040518	US 2000-630940	20000802
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002147143	A1	20021010	US 2001-897778	20010628
US 2003064947	A1	20030403	US 2001-7700	20011130
US 6960570	B2	20051101		
US 2003138438	A1	20030724	US 2002-117982	20020405
US 2003236209	A1	20031225	US 2002-313986	20021204
US 2005261166	A1	20051124	US 2003-623155	20030717
US 2004235072	A1	20041125	US 2004-775972	20040210
US 2005142620	A1	20050630	US 2004-922124	20040819

PRIORITY APPLN. INFO.:

US 1998-40802	B2	19980318
US 1998-123912	A2	19980727
US 1998-221107	A2	19981222
WO 1999-US5798	A1	19990317
US 1999-285479	A2	19990402
US 1999-466396	A2	19991217
US 1999-476496	A2	19991230
US 2000-480884	A2	20000110
US 2000-510376	A2	20000222
US 1998-40984	A	19980318
US 1998-123933	A	19980727
US 2000-542615	A2	20000404
US 2000-606421	A2	20000628
US 2000-630940	A2	20000802
US 2000-643597	A2	20000821
US 2000-662786	A2	20000915
US 2000-685696	A2	20001009
US 2000-735705	A2	20001212
US 2001-850716	A2	20010507
US 2001-897778	A2	20010628
US 2001-7700	A2	20011130
US 2002-117982	A2	20020405
US 2002-313986	A2	20021204
US 2003-623155	A2	20030717
US 2004-775972	A2	20040210

ED Entered STN: 13 Feb 2003

AB Compds. and methods for the treatment and diagnosis of lung cancer are provided. The inventive compds. include polypeptides containing at least a portion of a lung tumor protein. Vaccines and pharmaceutical compns. for immunotherapy of lung cancer comprising such polypeptides, or DNA mols. encoding such polypeptides, are also provided, together with DNA mols. for preparing the inventive polypeptides. Oligonucleotide probes and primers, and antibodies and methods and kits using these agents are also provided for monitoring lung cancer. The sequences of the lung tumor antigens were obtained from the cDNA libraries of human lung squamous cell carcinoma, lung adenocarcinoma, and metastatic lung adenocarcinoma.

IC ICM A01N043-04

ICS C12N015-63; C12N005-00; C07H021-04; A61K039-00

INCL 514044000; 435320100; 435325000; 435455000; 536023100; 536023500;
 424184100

CC 15-2 (Immunochimistry)

Section cross-reference(s): 1, 3, 9, 14, 63

IT 301546-68-9 301546-69-0 301546-70-3 301546-71-4 301546-72-5
 301546-73-6 301546-74-7 301546-75-8 301546-76-9 301546-77-0
 301546-78-1 301546-79-2 301546-80-5 301546-81-6 301546-82-7
301546-83-8 301546-84-9 301546-85-0 301546-86-1
 301546-87-2 301546-88-3 301546-89-4 301546-90-7 301546-91-8
 301546-92-9 301546-93-0

RL: ARU (Analytical role, unclassified); BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)

(lung tumor polypeptides, polynucleotides, and antibodies for therapy and diagnosis of lung cancer)

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:887119 CAPLUS

DOCUMENT NUMBER: 137:381946

TITLE: Method for determining the presence of lung cancer in a patient

INVENTOR(S): Wang, Tongtong; Hosken, Nancy A.; Kalos, Michael D.; Fanger, Gary R.; Fan, Liqun

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: U.S., 178 pp., Cont.--in-part of U.S. 476,496.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6482597	B1	20021119	US 2000-480884	20000110
US 6312695	B1	20011106	US 1998-123912	19980727
US 6660838	B1	20031209	US 1998-221107	19981222
WO 9947674	A2	19990923	WO 1999-US5798	19990317
WO 9947674	A3	20000120		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
CA 2369578	AA	20001019	CA 2000-2369578	20000403
WO 2000061612	A2	20001019	WO 2000-US8896	20000403
WO 2000061612	A3	20010426		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

EP 1169347	A2	20020109	EP 2000-920102	20000403
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000009505	A	20020611	BR 2000-9505	20000403
JP 2002543769	T2	20021224	JP 2000-611554	20000403
NZ 514818	A	20040430	NZ 2000-514818	20000403
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
US 6737514	B1	20040518	US 2000-630940	20000802
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002147143	A1	20021010	US 2001-897778	20010628
US 2003064947	A1	20030403	US 2001-7700	20011130
US 6960570	B2	20051101		
US 2003138438	A1	20030724	US 2002-117982	20020405
US 2003236209	A1	20031225	US 2002-313986	20021204
US 2005261166	A1	20051124	US 2003-623155	20030717
US 2004235072	A1	20041125	US 2004-775972	20040210
US 2005142620	A1	20050630	US 2004-922124	20040819
PRIORITY APPLN. INFO.:			US 1998-40802	A2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			WO 1999-US5798	W 19990317
			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 1998-40984	A 19980318
			US 1998-123933	A 19980727
			US 2000-480884	A 20000110
			US 2000-510376	A 20000222
			WO 2000-US8896	W 20000403
			US 2000-542615	A2 20000404
			US 2000-606421	A2 20000628
			US 2000-630940	A2 20000802
			US 2000-643597	A2 20000821
			US 2000-662786	A2 20000915
			US 2000-685696	A2 20001009
			US 2000-735705	A2 20001212
			US 2001-850716	A2 20010507
			US 2001-897778	A2 20010628
			US 2001-7700	A2 20011130
			US 2002-117982	A2 20020405
			US 2002-313986	A2 20021204
			US 2003-623155	A2 20030717
			US 2004-775972	A2 20040210

ED Entered STN: 22 Nov 2002

AB The invention concerns determining the presence of lung cancer from biol. sample. The association of the binding agent, antibody, and the lung cancer-associated peptide is compared to cut-off values to indicate the presence of lung cancer in a patient. Further, the invention concerns compds. and methods for the treatment and diagnosis of lung cancer. The inventive compds. include polypeptides containing at least a portion of a lung tumor protein. Vaccines and pharmaceutical compns. for immunotherapy of lung cancer comprising such polypeptides, or DNA mols. encoding such polypeptides, are also provided, together with DNA mols. for preparing the inventive polypeptides.

IC ICM G01N033-53

ICS G01N033-574; C07K016-00; A61K039-395

INCL 435007100

CC 9-10 (Biochemical Methods)

Section cross-reference(s): 14, 15

IT 301546-68-9 301546-69-0 301546-70-3 301546-71-4 301546-72-5
 301546-73-6 301546-74-7 301546-75-8 301546-76-9 301546-77-0
 301546-78-1 301546-79-2 301546-80-5 301546-81-6 301546-82-7
301546-83-8 301546-84-9 301546-85-0 301546-86-1
 301546-87-2 301546-88-3 301546-89-4 301546-90-7 301546-91-8
 301546-92-9 301546-93-0

RL: PRP (Properties)

(unclaimed sequence; method for determining the presence of lung cancer in a patient)

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:778703 CAPLUS

DOCUMENT NUMBER: 137:290681

TITLE: Lung cancer-associated cDNAs and proteins and their use in diagnosis and therapy

INVENTOR(S): Wang, Tongtong; Durham, Margarita; Fanger, Gary R.; Vedvick, Thomas S.; Carter, Darrick; Watanabe, Yoshihiro; Henderson, Robert A.; Peckham, David W.; Fanger, Neil

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: U.S. Pat. Appl. Publ., 287 pp., Cont.-in-part of U.S. Ser. No. 850,716.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002147143	A1	20021010	US 2001-897778	20010628
US 6312695	B1	20011106	US 1998-123912	19980727
US 6660838	B1	20031209	US 1998-221107	19981222
US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
US 6737514	B1	20040518	US 2000-630940	20000802
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002115139	A1	20020822	US 2001-850716	20010507
WO 2002047534	A2	20020620	WO 2001-US47576	20011130
WO 2002047534	A3	20020822		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002028940	A5	20020624	AU 2002-28940	20011130
US 2003064947	A1	20030403	US 2001-7700	20011130

US 6960570	B2	20051101		
EP 1351967	A2	20031015	EP 2001-990067	20011130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004523222	T2	20040805	JP 2002-549116	20011130
US 2003138438	A1	20030724	US 2002-117982	20020405
US 2003236209	A1	20031225	US 2002-313986	20021204
US 2005261166	A1	20051124	US 2003-623155	20030717
US 2004235072	A1	20041125	US 2004-775972	20040210
US 2005142620	A1	20050630	US 2004-922124	20040819
PRIORITY APPLN. INFO.:			US 1998-40802	A2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 2000-480884	A2 20000110
			US 2000-510376	A2 20000222
			US 2000-542615	A2 20000404
			US 2000-606421	A2 20000628
			US 2000-630940	A2 20000802
			US 2000-643597	A2 20000821
			US 2000-662786	A2 20000915
			US 2000-685696	A2 20001009
			US 2000-735705	A2 20001212
			US 2001-850716	A2 20010507
			WO 1999-US5798	A1 19990317
			US 2001-897778	A 20010628
			US 2001-7700	A2 20011130
			WO 2001-US47576	W 20011130
			US 2002-117982	A2 20020405
			US 2002-313986	A2 20021204
			US 2003-623155	A2 20030717
			US 2004-775972	A2 20040210

ED Entered STN: 11 Oct 2002

AB The cDNAs and corresponding proteins corresponding to mRNAs differentially expressed in lung squamous cell carcinoma and lung adenocarcinoma are disclosed. Antibodies to the lung cancer-associated proteins and probes for lung cancer-associated nucleic acids may be used in diagnosis of lung cancer. The proteins and cDNAs, antibodies to the proteins, T cells specific for these tumor proteins, and antigen-presenting cells expressing an epitope of these proteins may be used in treatment of lung cancer, e.g., in vaccines. Thus, many novel lung cancer-associated cDNAs/proteins were identified and their expression in normal and tumor tissues examined. Some of these cDNAs were expressed in E. coli, HEK293, and CHL-1 cells. N- and C-terminal fragments of one of the proteins were expressed as fusions with Mycobacterium tuberculosis 32-kilodalton serine proteinase-derived peptide. CTL lines specific for one of the tumor antigens were generated by in vitro whole-gene priming.

IC ICM A61K048-00
ICS A61K038-17; C07H021-04; C12N009-00; C12P021-02; C12N005-06; C07K014-435

INCL 514012000

CC 6-3 (General Biochemistry)

Section cross-reference(s): 1, 3, 14, 15

IT	301546-68-9	301546-69-0	301546-70-3	301546-71-4	301546-72-5
	301546-73-6	301546-74-7	301546-75-8	301546-76-9	301546-77-0
	301546-78-1	301546-79-2	301546-80-5	301546-81-6	301546-82-7
	301546-83-8	301546-84-9	301546-85-0	301546-86-1	
	301546-87-2	301546-88-3	301546-89-4	301546-90-7	301546-91-8

301546-92-9	301546-93-0	387817-58-5	387817-59-6	387817-60-9
387817-61-0	387817-62-1	387817-63-2	387817-64-3	387817-65-4
387817-66-5	387817-67-6	387817-68-7	387817-69-8	387817-70-1
387817-71-2	387817-72-3	387817-73-4	387817-74-5	387817-75-6
387817-76-7	387817-77-8	387817-78-9	387817-79-0	387817-80-3
387817-81-4	387817-82-5	387817-83-6	387817-84-7	387817-85-8
387817-86-9	387817-87-0	387817-88-1	387817-89-2	387817-90-5
387817-91-6	387817-92-7	387817-93-8	387817-94-9	387817-95-0

RL: PRP (Properties)

(unclaimed sequence; lung cancer-associated cDNAs and proteins and their use in diagnosis and therapy)

L5 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:638210 CAPLUS

DOCUMENT NUMBER: 137:196735

TITLE: Differentially expressed sequences and proteins for use in the therapy and diagnosis of human lung cancer
INVENTOR(S): Kalos, Michael D.; McNeill, Patricia D.; Retter, Marc W.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 276 pp., Cont.-in-part of U.S. Ser. No. 735,705.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002115139	A1	20020822	US 2001-850716	20010507
US 2002052329	A1	20020502	US 2000-735705	20001212
WO 2002000174	A2	20020103	WO 2001-US21065	20010628
WO 2002000174	A3	20030410		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2001073149	A5	20020108	AU 2001-73149	20010628
US 2002147143	A1	20021010	US 2001-897778	20010628
EP 1319069	A2	20030618	EP 2001-952390	20010628
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004513615	T2	20040513	JP 2002-504957	20010628
WO 2002047534	A2	20020620	WO 2001-US47576	20011130
WO 2002047534	A3	20020822		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,			

GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002028940	A5	20020624	AU 2002-28940	20011130
US 2003064947	A1	20030403	US 2001-7700	20011130
US 6960570	B2	20051101		
EP 1351967	A2	20031015	EP 2001-990067	20011130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004523222	T2	20040805	JP 2002-549116	20011130
US 2003138438	A1	20030724	US 2002-117982	20020405
US 2003236209	A1	20031225	US 2002-313986	20021204
US 2005261166	A1	20051124	US 2003-623155	20030717
US 2004235072	A1	20041125	US 2004-775972	20040210
US 2005142620	A1	20050630	US 2004-922124	20040819
PRIORITY APPLN. INFO.:			US 2000-735705	A2 20001212
			US 1998-40802	A2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 2000-480884	A2 20000110
			US 2000-510376	A2 20000222
			US 2000-542615	A2 20000404
			US 2000-606421	A2 20000628
			US 2000-630940	A2 20000802
			US 2000-643597	A2 20000821
			US 2000-662786	A2 20000915
			US 2000-685696	A2 20001009
			US 2001-850716	A 20010507
			US 2001-897778	A 20010628
			WO 2001-US21065	W 20010628
			US 2001-7700	A2 20011130
			WO 2001-US47576	W 20011130
			US 2002-117982	A2 20020405
			US 2002-313986	A2 20021204
			US 2003-623155	A2 20030717
			US 2004-775972	A2 20040210

ED Entered STN: 23 Aug 2002

AB Lung-specific expressed genes (cDNA) and their encoded proteins useful for the therapy and diagnosis of cancer, particularly lung cancer, are identified. Illustrative compns. comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

IC ICM C12N009-00
ICS C07H021-04; C12P021-02; C07K014-435; C12N005-06

INCL 435069100

CC 3-3 (Biochemical Genetics)
Section cross-reference(s): 1, 9, 14, 15, 63

IT 301546-69-0 301546-71-4 301546-72-5 301546-73-6 301546-74-7
301546-75-8 301546-76-9 301546-77-0 301546-78-1 301546-79-2
301546-80-5 301546-81-6 301546-82-7 301546-83-8
301546-84-9 301546-85-0 301546-86-1 301546-87-2 301546-88-3
301546-89-4 301546-90-7 301546-91-8 301546-92-9 301546-93-0
449759-84-6 449759-87-9

RL: ANT (Analyte); BSU (Biological study, unclassified); DGN (Diagnostic

use); PRP (Properties); THU (Therapeutic use); ANST (Analytical study);
 BIOL (Biological study); USES (Uses)
 (L726P-derived peptide; differentially expressed sequences and proteins
 for use in therapy and diagnosis of human lung cancer)

L5 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:570640 CAPLUS
 DOCUMENT NUMBER: 137:139349
 TITLE: Lung tumor proteins, polynucleotides and antibodies
 for therapy and diagnosis of lung cancer
 INVENTOR(S): Wang, Tongtong; Fan, Liqun; Kalos, Michael D.; Bangur,
 Chaitanya S.; Hosken, Nancy A.; Fanger, Gary R.; Li,
 Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.;
 Henderson, Robert A.; McNeill, Patricia D.
 PATENT ASSIGNEE(S): Corixa Corporation, USA
 SOURCE: U.S., 233 pp., Cont.-in-part of U.S. Ser. No. 630,940.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 22
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6426072	B1	20020730	US 2000-643597	20000821
US 6737514	B1	20040518	US 2000-630940	20000802
US 2002052329	A1	20020502	US 2000-735705	20001212
WO 2002000174	A2	20020103	WO 2001-US21065	20010628
WO 2002000174	A3	20030410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001073149	A5	20020108	AU 2001-73149	20010628
US 2002147143	A1	20021010	US 2001-897778	20010628
EP 1319069	A2	20030618	EP 2001-952390	20010628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004513615	T2	20040513	JP 2002-504957	20010628
US 2003064947	A1	20030403	US 2001-7700	20011130
US 6960570	B2	20051101		
US 2003138438	A1	20030724	US 2002-117982	20020405
US 2003236209	A1	20031225	US 2002-313986	20021204
US 2005261166	A1	20051124	US 2003-623155	20030717
US 2004235072	A1	20041125	US 2004-775972	20040210
US 2005142620	A1	20050630	US 2004-922124	20040819
PRIORITY APPLN. INFO.:			US 2000-630940	A2 20000802
			US 1998-40802	A2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 2000-480884	A2 20000110

US 2000-510376	A2 20000222
US 2000-542615	A2 20000404
US 2000-606421	A2 20000628
US 2000-643597	A2 20000821
US 2000-662786	A2 20000915
US 2000-685696	A2 20001009
US 2000-735705	A 20001212
US 2001-850716	A 20010507
US 2001-897778	A2 20010628
WO 2001-US21065	W 20010628
US 2001-7700	A2 20011130
US 2002-117982	A2 20020405
US 2002-313986	A2 20021204
US 2003-623155	A2 20030717
US 2004-775972	A2 20040210

ED Entered STN: 01 Aug 2002

AB Compns. and methods for the therapy and diagnosis of cancer, such as lung cancer, are disclosed. Compns. may comprise one or more lung tumor proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a lung tumor protein, or a T cell that is specific for cells expressing such a protein. Such compns. may be used, for example, for the prevention and treatment of diseases such as lung cancer. Diagnostic methods based on detecting a lung tumor protein (by immunoassay with antibodies, monoclonal antibodies or fragments), or mRNA encoding such a protein (by hybridization with oligonucleotide probes and primers), in a sample are also provided.

IC ICM A61K039-00

ICS C07H021-04; C12N015-63; C07K005-00; C07K014-00

INCL 424184100

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3, 9, 63

IT	301546-68-9	301546-69-0	301546-70-3	301546-71-4	301546-72-5
	301546-73-6	301546-74-7	301546-75-8	301546-76-9	301546-77-0
	301546-78-1	301546-79-2	301546-80-5	301546-81-6	301546-82-7
	301546-83-8	301546-84-9	301546-85-0	301546-86-1	
	301546-87-2	301546-88-3	301546-89-4	301546-90-7	301546-91-8
	301546-92-9	301546-93-0	387817-58-5	387817-59-6	

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lung tumor proteins, polynucleotides and antibodies for therapy and diagnosis of lung cancer)

REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:332673 CAPLUS

DOCUMENT NUMBER: 136:354185

TITLE: Lung tumor-specific antigen, chimeric antigens, polynucleotides, and antibodies for therapy and diagnosis of lung cancer

INVENTOR(S): Wang, Tongtong; Fan, Liqun; Kalos, Michael D.; Bangur, Chaitanya S.; Hosken, Nancy A.; Fanger, Gary R.; Li, Samuel X.; Wang, Aijun; Skeiky, Yasir A. W.; Henderson, Robert A.; McNeill, Patricia D.; Fanger, Neil

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 259 pp., Cont.-in-part of U.S. Ser. No. 685,696.
CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 22
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002052329	A1	20020502	US 2000-735705	20001212
US 6312695	B1	20011106	US 1998-123912	19980727
US 6660838	B1	20031209	US 1998-221107	19981222
US 6821518	B1	20041123	US 1999-285479	19990402
US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
US 6518256	B1	20030211	US 2000-542615	20000404
US 6531315	B1	20030311	US 2000-606421	20000628
US 6737514	B1	20040518	US 2000-630940	20000802
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002115139	A1	20020822	US 2001-850716	20010507
WO 2002000174	A2	20020103	WO 2001-US21065	20010628
WO 2002000174	A3	20030410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001073149	A5	20020108	AU 2001-73149	20010628
US 2002147143	A1	20021010	US 2001-897778	20010628
EP 1319069	A2	20030618	EP 2001-952390	20010628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004513615	T2	20040513	JP 2002-504957	20010628
WO 2002047534	A2	20020620	WO 2001-US47576	20011130
WO 2002047534	A3	20020822		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002028940	A5	20020624	AU 2002-28940	20011130
US 2003064947	A1	20030403	US 2001-7700	20011130
US 6960570	B2	20051101		
EP 1351967	A2	20031015	EP 2001-990067	20011130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004523222	T2	20040805	JP 2002-549116	20011130
US 2003138438	A1	20030724	US 2002-117982	20020405
US 2003236209	A1	20031225	US 2002-313986	20021204
US 2005261166	A1	20051124	US 2003-623155	20030717

US 2004235072	A1	20041125	US 2004-775972	20040210
US 2005142620	A1	20050630	US 2004-922124	20040819
PRIORITY APPLN. INFO.:			US 1998-40802	A2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 2000-480884	A2 20000110
			US 2000-510376	A2 20000222
			US 2000-542615	A2 20000404
			US 2000-606421	A2 20000628
			US 2000-630940	A2 20000802
			US 2000-643597	A2 20000821
			US 2000-662786	A2 20000915
			US 2000-685696	A2 20001009
			WO 1999-US5798	A1 19990317
			US 2000-735705	A2 20001212
			US 2001-850716	A 20010507
			US 2001-897778	A 20010628
			WO 2001-US21065	W 20010628
			US 2001-7700	A2 20011130
			WO 2001-US47576	W 20011130
			US 2002-117982	A2 20020405
			US 2002-313986	A2 20021204
			US 2003-623155	A2 20030717
			US 2004-775972	A2 20040210

ED Entered STN: 03 May 2002

AB Compns. and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compns. comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

IC ICM A61K048-00

ICS C12Q001-68; G01N033-574; C07H021-04; C12N009-00

INCL 514044000

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3, 9, 63

IT	301546-68-9	301546-69-0	301546-70-3	301546-71-4	301546-72-5
	301546-73-6	301546-74-7	301546-75-8	301546-76-9	301546-77-0
	301546-78-1	301546-79-2	301546-80-5	301546-81-6	301546-82-7
	301546-83-8	301546-84-9	301546-85-0	301546-86-1	
	301546-87-2	301546-88-3	301546-89-4	301546-90-7	301546-91-8
	301546-92-9	301546-93-0	387817-59-6	387817-60-9	387817-61-0
	387817-62-1	387817-63-2	387817-64-3	387817-65-4	387817-66-5
	387817-67-6	387817-68-7	387817-69-8	387817-70-1	387817-71-2
	387817-73-4	387817-74-5	387817-75-6	387817-76-7	387817-77-8
	387817-78-9	387817-79-0	387817-80-3	387817-81-4	387817-82-5
	387817-83-6	387817-84-7	387817-85-8	387817-86-9	387817-87-0
	387817-88-1	387817-89-2	387817-90-5	387817-91-6	387817-92-7
	387817-93-8	387817-94-9	421594-89-0	421600-44-4	421600-45-5
	421600-46-6	421600-47-7	421600-48-8	421600-49-9	421600-50-2
	421600-51-3				

RL: BSU (Biological study, unclassified); DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (lung tumor-specific antigen, chimeric antigens, polynucleotides, and antibodies for therapy and diagnosis of lung cancer)

L5 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2002:10236 CAPLUS

DOCUMENT NUMBER: 136:101081

TITLE: Compositions and methods for the therapy and diagnosis of lung cancer

INVENTOR(S): Wang, Tongtong; Wang, Aijun; Skeiky, Yasir A. W.; Li, Samuel X.; Kalos, Michael D.; Henderson, Robert A.; Mcneill, Patricia D.; Fanger, Neil; Retter, Marc W.; Marnerakis, Margarita; Fanger, Gary Richard; Vedvick, Thomas S.; Carter, Darrick; Watanabe, Yoshihiro; Peckham, David W.

PATENT ASSIGNEE(S): Corixa Corp., USA

SOURCE: PCT Int. Appl., 374 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000174	A2	20020103	WO 2001-US21065	20010628
WO 2002000174	A3	20030410		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6531315	B1	20030311	US 2000-606421	20000628
US 6737514	B1	20040518	US 2000-630940	20000802
US 6426072	B1	20020730	US 2000-643597	20000821
US 2002052329	A1	20020502	US 2000-735705	20001212
US 2002115139	A1	20020822	US 2001-850716	20010507
AU 2001073149	A5	20020108	AU 2001-73149	20010628
EP 1319069	A2	20030618	EP 2001-952390	20010628
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004513615	T2	20040513	JP 2002-504957	20010628
PRIORITY APPLN. INFO.:				
			US 2000-606421	A 20000628
			US 2000-630940	A 20000802
			US 2000-643597	A 20000821
			US 2000-662786	A 20000915
			US 2000-685696	A 20001009
			US 2000-735705	A 20001212
			US 2001-850716	A 20010507
			US 1998-40802	B2 19980318
			US 1998-123912	A2 19980727
			US 1998-221107	A2 19981222
			WO 1999-US5798	A1 19990317
			US 1999-285479	A2 19990402
			US 1999-466396	A2 19991217
			US 1999-476496	A2 19991230
			US 2000-480884	A2 20000110
			US 2000-510376	A2 20000222

US 2000-542615 A2 20000404
WO 2001-US21065 W 20010628

ED Entered STN: 04 Jan 2002

AB Compns. and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compns. comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compns. are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly lung cancer.

IC ICM A61K

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3, 9, 63

IT 301546-68-9 301546-69-0 301546-70-3 301546-71-4 301546-72-5
301546-73-6 301546-74-7 301546-75-8 301546-76-9 301546-77-0
301546-78-1 301546-79-2 301546-80-5 301546-81-6 301546-82-7
301546-83-8 301546-84-9 301546-85-0 301546-86-1
301546-87-2 301546-88-3 301546-89-4 301546-90-7 301546-91-8
301546-92-9 301546-93-0 387817-62-1 387817-63-2 387817-64-3
387817-65-4 387817-66-5 387817-67-6 387817-68-7 387817-69-8
387817-70-1 387817-71-2 387817-72-3 387817-73-4 387817-74-5
387817-75-6 387817-76-7 387817-77-8 387817-78-9 387817-79-0
387817-80-3 387817-81-4 387817-82-5 387817-83-6 387817-84-7
387817-85-8 387817-86-9 387817-87-0 387817-88-1 387817-89-2
387817-90-5 387817-91-6 387817-92-7 387817-93-8 387817-94-9
387817-95-0 387817-96-1 387817-97-2 387817-98-3 387817-99-4
387818-00-0 387818-01-1 387818-02-2 387818-03-3 387818-04-4
387818-05-5 387818-06-6

RL: PRP (Properties)

(unclaimed sequence; compns. and methods for the therapy and diagnosis of lung cancer)

L5 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:742121 CAPLUS

DOCUMENT NUMBER: 133:308983

TITLE: Compounds and methods for therapy and diagnosis of lung cancer

INVENTOR(S): Wang, Tongtong; Fan, Liquan

PATENT ASSIGNEE(S): Corixa Corporation, USA

SOURCE: PCT Int. Appl., 261 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 22

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061612	A2	20001019	WO 2000-US8896	20000403
WO 2000061612	A3	20010426		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6821518	B1	20041123	US 1999-285479	19990402

Brandon Fetterolf 10/779,949

US 2003119763	A1	20030626	US 1999-466396	19991217
US 6696247	B2	20040224		
US 6706262	B1	20040316	US 1999-476496	19991230
US 6482597	B1	20021119	US 2000-480884	20000110
CA 2369578	AA	20001019	CA 2000-2369578	20000403
EP 1169347	A2	20020109	EP 2000-920102	20000403

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO

BR 2000009505	A	20020611	BR 2000-9505	20000403
JP 2002543769	T2	20021224	JP 2000-611554	20000403
NZ 514818	A	20040430	NZ 2000-514818	20000403

PRIORITY APPLN. INFO.:

US 1999-285479	A	19990402
US 1999-466396	A	19991217
US 1999-476496	A	19991230
US 2000-480884	A	20000110
US 2000-510376	A	20000222
US 1998-40802	B2	19980318
US 1998-123912	A2	19980727
US 1998-221107	A2	19981222
WO 1999-US5798	A1	19990317
WO 2000-US8896	W	20000403

ED Entered STN: 20 Oct 2000

AB Compds. and methods for the treatment and diagnosis of lung cancer are provided. The inventive compds. include polypeptides containing at least a portion of a lung tumor protein. Vaccines and pharmaceutical compns. for immunotherapy of lung cancer comprising such polypeptides, or DNA mols. encoding such polypeptides, are also provided, together with DNA mols. for preparing the inventive polypeptides.

IC ICM C07K014-00

CC 15-2 (Immunochemistry)

Section cross-reference(s): 3

IT 301546-68-9	301546-69-0	301546-70-3	301546-71-4	301546-72-5
301546-73-6	301546-74-7	301546-75-8	301546-76-9	301546-77-0
301546-78-1	301546-79-2	301546-80-5	301546-81-6	301546-82-7
301546-83-8	301546-84-9	301546-85-0	301546-86-1	
301546-87-2	301546-88-3	301546-89-4	301546-90-7	301546-91-8
301546-92-9	301546-93-0			

RL: BSU (Biological study, unclassified); PRP (Properties); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)

(lung tumor proteins and DNA encoding them for therapy and diagnosis of lung cancer)